Intended for healthcare professionals

Letters Illegal drugs market

Illegal drugs in the UK—we need better screening and surveillance

BMJ 2024; 384 doi: https://doi.org/10.1136/bmj.q2 (Published 02 January 2024) Cite this as: BMJ 2024;384:q2
  1. Rob Moore, principal clinical scientist,
  2. Rebecca Wood, clinical scientist
  1. Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton and Hove, UK
  1. robert.moore8{at}nhs.net

We agree with the concerns raised by Eastwood and Schlossenberg about the changing drug landscape in the UK.1 There is a need in healthcare for a functional surveillance system to identify emerging threats.

Regrettably, the availability of analytical toxicology services in the NHS is exceptionally disparate. Apart from a few very specialist laboratories, a significant amount of …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription